ReviewProceedings of the Japan Academy. Series B, Physical and biological sciences2010
A new paradigm of bacteria-gut interplay brought through the study of Shigella.
Review in Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 28 citations in OpenAlex.
- Bacteriophage Therapy AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Natural phytochemicals that affect autophagy in the treatment of oral diseases and infections: A review.Frontiers in pharmacology · 2022Review
- Bacterial nucleomodulins: A coevolutionary adaptation to the eukaryotic command center.PLoS pathogens · 2021Review
- Bacterial Actin-Specific Endoproteases Grimelysin and Protealysin as Virulence Factors Contributing to the Invasive Activities ofInternational journal of molecular sciences · 2020Review
- A Brief History ofEcoSal Plus · 2018Review
- TheBiochemistry and biophysics reports · 2016Article
- Gut microbiota as potential orchestrators of irritable bowel syndrome.Gut and liver · 2015Review
- Role of intracellular carbon metabolism pathways in Shigella flexneri virulence.Infection and immunity · 2014Article
- Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection.World journal of gastroenterology · 2014Review
- Tropism and pathogenicity of rickettsiae.Frontiers in microbiology · 2012Article
- Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system.Journal of inflammation (London, England) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria-gut epithelial interplay and the mucosal immune response are the most critical issues in determining the fate of bacterial infection and the severity of diseases. Shigella species (abbreviated here as Shigella), the causative agent of bacillary dysentery (shigellosis), are highly adapted human pathogens that are capable of invading and colonizing the intestinal epithelium, which results in severe inflammatory colitis. Shigella secrete a large and diverse number (more then 50) of effectors via the type III secretion system (TTSS) during infection, some of which are delivered into the surrounding bacterial space and some others into the host cell cytoplasm and nucleus. The delivered effectors mimic and usurp the host cellular functions, and modulate host cell signaling and immune response, thus playing pivotal roles in promoting bacterial infection and circumventing host defense systems. This article overviews the pathogenic characteristics of Shigella, and highlights current topics related to the bacterial infectious stratagem executed by the TTSS-secreted effectors. Though bacterial stratagems and the molecular mechanisms of infection vary greatly among pathogens, the current studies of Shigella provide a paradigm shift in bacterial pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.